Abstract
Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.
| Original language | English |
|---|---|
| Pages (from-to) | 286-294 |
| Number of pages | 9 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 66 |
| Issue number | 4 |
| State | Published - 1980 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology
- Immunology and Allergy
Cite this
Protective effect of lodoxamide tromethamine on allergen inhalation challenge. / Watt, G. D.; Bui, T. C.; Bewtra, Againdra K.; Townley, R. G.
In: Journal of Allergy and Clinical Immunology, Vol. 66, No. 4, 1980, p. 286-294.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Protective effect of lodoxamide tromethamine on allergen inhalation challenge
AU - Watt, G. D.
AU - Bui, T. C.
AU - Bewtra, Againdra K.
AU - Townley, R. G.
PY - 1980
Y1 - 1980
N2 - Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.
AB - Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.
UR - http://www.scopus.com/inward/record.url?scp=0018910126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018910126&partnerID=8YFLogxK
M3 - Article
VL - 66
SP - 286
EP - 294
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 4
ER -